Aveta Biomics Announces Abstract Acceptance for Presentation at the 2025 ASCO Annual Meeting
Aveta Biomics to present the results from Phase 2A trial of APG-157 as neoadjuvant monotherapy for head and neck cancer at ASCO 2025. Press Release ASCO 2025 Announcement